Strategy for the management of diabetic macular edema: The European vitreo-retinal society macular edema study

BioMed Research International

Volumn 2015, Issue , 2015, Pages

  Adelman, Ron ^a   Parnes, Aaron ^b   Michalewska, Zofia ^c   Parolini, Barbara ^d   Boscher, Claude ^e   Ducournau, Didier ^f  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Eyecare Medical Group   (United States)

^c Ophthalmic Clinic Jasne Blonia   (Poland)

^d S ANNA HOSPITAL   (Italy)

^e AMERICAN HOSPITAL OF PARIS   (France)

^f EVRS   (France)

Author keywords

[No Author keywords available]

Indexed keywords

TRIAMCINOLONE; VASCULOTROPIN INHIBITOR;

ARTICLE; CATARACTOGENESIS; CILIARY DISK; CLINICAL STUDY; DIABETIC MACULAR EDEMA; DRUG EFFICACY; FOLLOW UP; HUMAN; INTERNAL LIMITING MEMBRANE; LASER COAGULATION; MAJOR CLINICAL STUDY; MANAGED CARE; MEDICAL INFORMATION; MEDICAL SOCIETY; MONOTHERAPY; MULTICENTER STUDY; OUTCOME ASSESSMENT; POSTOPERATIVE COMPLICATION; RETINA DETACHMENT; STRATEGIC PLANNING; TIME TO TREATMENT; VISION; VISUAL ACUITY; VITRECTOMY; BASEMENT MEMBRANE; CLINICAL TRIAL; DIABETIC RETINOPATHY; DISEASE MANAGEMENT; MACULAR EDEMA; PATHOLOGY; PHYSIOLOGY; PROCEDURES; RETINA;

BASEMENT MEMBRANE; DIABETIC RETINOPATHY; DISEASE MANAGEMENT; HUMANS; MACULAR EDEMA; RETINA; VISUAL ACUITY; VITRECTOMY;

EID: 84933037839     PISSN: 23146133     EISSN: 23146141     Source Type: Journal    
DOI: 10.1155/2015/352487     Document Type: Article

References (49)

1. R. Klein, B. E. K. Klein, S. E. Moss, M. D. Davis, and D. L. DeMets, "The Wisconsin epidemiologic study of diabetic retinopathy. IV. Diabetic macular edema," Ophthalmology, vol. 91, no. 12, pp. 1464-1474, 1984.
2. J. W. Y. Yau, S. L. Rogers, R.Kawasaki et al., "Global prevalence and major risk factors of diabetic retinopathy," Diabetes Care, vol. 35, no. 3, pp. 556-564, 2012.
3. Early Treatment Diabetic Retinopathy Study Research Group, "Photocoagulation for diabetic macular edema. Early treatment diabetic retinopathy study report number 1," Archives of Ophthalmology, vol. 103, pp. 1796-1806, 1985.
4. C. Haritoglou, D. Kook, A. Neubauer et al., "Intravitreal bevacizumab (Avastin) therapy for persistent diffuse diabetic macular edema," Retina, vol. 26, no. 9, pp. 999-1005, 2006.
5. J. F. Arevalo, J. G. Sanchez, A. F. Lasave et al., "Intravitreal Bevacizumab (Avastin) for Diabetic Retinopathy at 24-months: The 2008 Juan Verdaguer-Planas Lecture," Current Diabetes Reviews, vol. 6, no. 5, pp. 313-322, 2008.
6. Q. D. Nguyen, D. M. Brown, D. M.Marcus et al., "Ranibizumab for diabeticmacular edema: results from2 phase iii randomized trials: RISE and RIDE," Ophthalmology, vol. 119, no. 4, pp. 789-801, 2012.
7. Q. D. Nguyen, S. M. Shah, A. A. Khwaja et al., "Two-year outcomes of the ranibizumab for edema of the mAcula in diabetes (READ-2) study," Ophthalmology, vol. 117, no. 11, pp.2146-2151, 2010.
8. M.Michaelides, A. Kaines, R. D. Hamilton et al., "A prospective randomized trial of intravitreal bevacizumab or laser therapy in the management of diabetic macular edema (BOLT study) 12-month data: report 2," Ophthalmology, vol. 117, no. 6, pp. 1078-1086, 2010.
9. P. Massin, F. Bandello, J. G. Garweg et al., "Safety and efficacy of ranibizumab in diabeticmacular edema (RESOLVE study): a12-month, randomized, controlled, double-masked, multicenter phase II study," Diabetes Care, vol. 33, no. 11, pp. 2399-2405, 2010.
10. D. V. Do, Q. D. Nguyen, D. Boyer et al., "One-year outcomes of the da VINCI study of VEGF trap-eye in eyes with diabeticmacular edema," Ophthalmology, vol. 119, no. 8, pp. 1658-1665,2012.
11. Diabetic Retinopathy Clinical Research Network, M. J. Elman, H. Qin et al., "Intravitreal ranibizumab for diabetic macular edema with prompt versus deferred laser treatment: three-year randomized trial results," Ophthalmology, vol. 119, pp. 2312-2318, 2012.
12. M. Soheilian, A. Ramezani, A. Obudi et al., "Randomized trial of intravitreal bevacizumab alone or combined with triamcinolone versus macular photocoagulation in diabetic macular edema," Ophthalmology, vol. 116, no. 6, pp. 1142-1150, 2009.
13. I. Zucchiatti, R. Lattanzio, G. Querques et al., "Intravitreal dexamethasone implant in patients with persistent diabetic macular edema," Ophthalmologica, vol. 228, no. 2, pp. 117-122,2012.
14. P. A. Campochiaro, D. M. Brown, A. Pearson et al., "Sustained delivery fluocinolone acetonide vitreous inserts provide benefit for at least 3 years in patients with diabetic macular edema," Ophthalmology, vol. 119, no. 10, pp. 2125-2132, 2012.
15. M. C. Gillies, F. K. P. Sutter, J. M. Simpson, J. Larsson, H. Ali, and M. Zhu, "Intravitreal triamcinolone for refractory diabetic macular edema: two-year results of a double-masked, placebocontrolled, randomized clinical trial," Ophthalmology, vol. 113, no. 9, pp. 1533-1538, 2006.
16. J. B. Jonas, B. A. Kamppeter, B. Harder, U. Vossmerbaeumer, G. Sauder, and U. H.M. Spandau, "Intravitreal triamcinolone acetonide for diabetic macular edema: a prospective, randomized study," Journal of Ocular Pharmacology and Therapeutics, vol. 22, no. 3, pp. 200-207, 2006.
17. T. Otani and S. Kishi, "A controlled study of vitrectomy for diabetic macular edema," American Journal of Ophthalmology, vol. 134, no. 2, pp. 214-219, 2002.
18. T. Kimura, J. Kiryu, H. Nishiwaki et al., "Efficacy of surgical removal of the internal limiting membrane in diabetic cystoid macular edema," Retina, vol. 25, no. 4, pp. 454-461, 2005.
19. P. Mitchell, F. Bandello, U. Schmidt-Erfurth et al., "The RESTORE study: ranibizumab monotherapy or combined with laser versus laser monotherapy for diabetic macular edema," Ophthalmology, vol. 118, no. 4, pp. 615-625, 2011.
20. J. F. Arevalo, A. F. Lasave, L.Wu et al., "Intravitreal bevacizumab plus grid laser photocoagulation or intravitreal bevacizumab or grid laser photocoagulation for diffuse diabeticmacular edema: results of the pan-american collaborative retina study group at 24 months," Retina, vol. 33, no. 2, pp. 403-413, 2013.
21. S. J. Lee, E. T. Kim, and Y. S. Moon, "Intravitreal bevacizumab alone versus combined with macular photocoagulation in diabetic macular edema," Korean Journal of Ophthalmology, vol. 25, no. 5, pp. 299-304, 2011.
22. M. Soheilian, A. Ramezani, A. Obudi et al., "Randomized trial of intravitreal bevacizumab alone or combined with triamcinolone versus macular photocoagulation in diabetic macular edema," Ophthalmology, vol. 116, no. 6, pp. 1142-1150, 2009.
23. Diabetic RetinopathyClinical ResearchNetwork, "Randomized trial evaluating ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema," Ophthalmology, vol. 117, no. 6, pp. 1064-1077, 2010.
24. G. Sobaci, G. Özge, C. Erdurman, H. A. Durukan, and Z. M. Bayraktar, "Comparison of grid laser, intravitreal triamcinolone, and intravitreal bevacizumab in the treatment of diffuse diabetic macular edema," Ophthalmologica, vol. 227, no. 2, pp. 95-99, 2012.
25. T. C. Kreutzer, R. Al Saeidi, D. Kook et al., "Comparison of intravitreal bevacizumab versus triamcinolone for the treatment of diffuse diabetic macular edema," Ophthalmologica, vol. 224, no. 4, pp. 258-264, 2010.
26. L. Paccola, R. A. Costa, M. S. Folgosa, J. C. Barbosa, I. U. Scott, and R. Jorge, "Intravitreal triamcinolone versus bevacizumab for treatment of refractory diabetic macular oedema (IBEME study)," British Journal of Ophthalmology, vol. 92, no. 1, pp. 76-80, 2008.
27. N. Doi, T. Sakamoto, Y. Sonoda et al., "Comparative study of vitrectomy versus intravitreous triamcinolone for diabetic macular edema on randomized paired-eyes," Graefe's Archive for Clinical and ExperimentalOphthalmology, vol. 250, no. 1,pp. 71-78, 2012.
28. A. Yanyali, A. F. Nohutcu, F. Horozoglu, and E. Celik, "Modified grid laser photocoagulation versus pars plana vitrectomy with internal limiting membrane removal in diabetic macular edema," The American Journal of Ophthalmology, vol. 139, no. 5, pp. 795-801, 2005.
29. R. A. Adelman, A. J. Parnes, and D. Ducournau, "Strategy for the management of uncomplicated retinal detachments: the european vitreo-retinal society retinal detachment study report 1," Ophthalmology, vol. 120, no. 9, pp. 1804-1808, 2013.
30. R. A. Adelman, A. J. Parnes, J. O. Sipperley, and D. Ducournau, "Strategy for the management of complex retinal detachments: the European vitreo-retinal society retinal detachment study report 2," Ophthalmology, vol. 120, no. 9, pp. 1809-1813, 2013.
31. Z. Michalewska, D. Ducournau, and R. A. Adelman, "How do vitrectomy parameters influence the results of rhegmatogenous retinal detachments repair? EVRS RD Study No. 3," Acta Ophthalmologica, vol. 92, no. 5, pp. e416-e417, 2014.
32. R. A. Adelman, A. J. Parnes, Z. Michalewska, D. Ducournau, and European Vitreo-Retinal Society (EVRS) Retinal Detachment Study Group, "Clinical variables associated with failure of retinal detachment repair: the European vitreo-retinal society retinal detachment study report number 4," Ophthalmology, vol. 121, no. 9, pp. 1715-1719, 2014.
33. D. V. Do, Q. D. Nguyen, A. A. Khwaja et al., "Ranibizumab for edema of the macula in diabetes study: 3-year outcomes and the need for prolonged frequent treatment," JAMA Ophthalmology, vol. 131, no. 2, pp. 139-145, 2013.
34. V. Kumar, B. Ghosh, D. K. Mehta, and N. Goel, "Functional outcome of subthreshold versus threshold diode laser photocoagulation in diabetic macular oedema," Eye, vol. 24, no. 9, pp. 1459-1465, 2010.
35. J.W. Lim, H. K. Lee, andM.C. Shin, "Comparison of intravitreal bevacizumab alone or combined with triamcinolone versus triamcinolone in diabetic macular edema: a randomized clinical trial," Ophthalmologica, vol. 227, no. 2, pp. 100-106, 2012.
36. H. M. Marey and A. F. Ellakwa, "Intravitreal bevacizumab alone or combinedwith triamcinolone acetonide as the primary treatment for diabetic macular edema," Clinical Ophthalmology, vol. 5, no. 1, pp. 1011-1016, 2011.
37. H. Y. Lee, S. Y. Lee, and J. S. Park, "Comparison of photocoagulation with combined intravitreal triamcinolone for diabetic macular edema," Korean Journal of Ophthalmology, vol. 23, no. 3, pp. 153-158, 2009.
38. T. J.Wolfensberger and Z. J.Gregor, "Macular edema-rationale for therapy," Developments in Ophthalmology, vol. 47, pp. 49-58, 2010.
39. N. M. Holekamp, Y.-B. Shui, and D. Beebe, "Lower intraocular oxygen tension in diabetic patients: possible contribution to decreased incidence of nuclear sclerotic cataract," American Journal of Ophthalmology, vol. 141, no. 6, pp. 1027-1032, 2006.
40. N. M. Holekamp, Y. B. Shui, and D. C. Beebe, "Vitrectomy surgery increases oxygen exposure to the lens: a possiblemechanism for nuclear cataract formation," The American Journal of Ophthalmology, vol. 139, no. 2, pp. 302-310, 2005.
41. S.Wolf,U. Schnurbusch, P.Wiedemann, J.Grosche, A. Reichenbach, and H. Wolburg, "Peeling of the basal membrane in the human retina: ultrastructural effects," Ophthalmology, vol. 111, no. 2, pp. 238-243, 2004.
42. A. Ophir, M. R. Martinez, P. Mosqueda, and A. Trevino, "Vitreous traction and epiretinal membranes in diabetic macular oedema using spectral-domain optical coherence tomography," Eye, vol. 24, no. 10, pp. 1545-1553, 2010.
43. S. Shibuya, O. Miyamoto, T. Itano, S. Mori, and H. Norimatsu, "Temporal progressive antigen expression in radial glia after contusive spinal cord injury in adult rats," GLIA, vol. 42, no. 2, pp. 172-183, 2003.
44. G. E. Goings, V. Sahni, and F. G. Szele, "Migration patterns of subventricular zone cells in adult mice change after cerebral cortex injury," Brain Research, vol. 996, no. 2, pp. 213-226, 2004.
45. G. P. Lewis and S. K. Fisher, "Up-regulation of glial fibrillary acidic protein in response to retinal injury: its potential role in glial remodeling and a comparison to vimentin expression," International Review of Cytology, vol. 230, pp. 263-290, 2003.
46. J. D. Unterlauft, W. Eichler, K. Kuhne et al., "Pigment epithelium-derived factor released by Müller glial cells exerts neuroprotective effects on retinal ganglion cells," Neurochemical Research, vol. 37, no. 7, pp. 1524-1533, 2012.
47. M. Wang, W. Ma, L. Zhao, R. N. Fariss, and W. T. Wong, "AdaptiveMüller cell responses to microglial activationmediate neuroprotection and coordinate inflammation in the retina," Journal of Neuroinflammation, vol. 8, article 173, 2011.
48. A. Madinier, "Microglial and BDNF impact on the induction of the postischemic neuroplasticity," Thesis 2011, http://www .theses.fr/2011DIJOS037/document.
49. I. L. McAllister, S. Vijayasekaran, S. D. Chen, and D. Y. Yu, "Effect of triamcinolone acetonide on vascular endothelial growth factor and occludin levels in branch retinal vein occlusion," TheAmerican Journal ofOphthalmology, vol. 147, no. 5,pp. 838-846, 2009.